MMM — Medicare/Medicaid
Medicare policies.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
1st Quarter - Report · 2026
- Filing UUID
84ba18cc-bc01-4699-acf6-c6b12e49c8e0- Type
Q1— 1st Quarter - Report- Period
- first_quarter
- Year
- 2026
- Posted
- 2026-04-20 16:03:56
- Income (reported)
- $60,000
- Expenses (reported)
- —
- Filing document
- Open on lda.senate.gov
Registrant (lobbying firm)
Law firm.
- Contact
- WILLIAM MINOR
- Phone
- +1 202-799-4312
- Address
- zip:20004, city:Washington, state:DC, street:500 8th Street, NW
Client
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Trade association of innovative biopharmaceutical research companies.
- State
- DC
- Country
- US
- Effective date
- 2025-01-01
Issues lobbied + lobbyists (7)
BUD — Budget/Appropriations
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
DEF — Defense
National security issues related to pharmaceutical industry, including supply chain.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
TRD — Trade (domestic/foreign)
Trade policies and agreements, including IP protections, and administrative tariff actions.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
CPT — Copyright/Patent/Trademark
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
PHA — Pharmacy
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
HCR — Health Issues
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE